Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

187.49 +0.55 (+0.29%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Beigene Ltd ADR

< Previous 1 2 3 4 5 6 7 8 Next >
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will... 
Via Talk Markets
BeiGene Earnings Perspective: Return On Capital Employed
Via Benzinga
PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday
Via Benzinga
What 5 Analyst Ratings Have To Say About BeiGene
Via Benzinga
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier. 
Via Investor's Business Daily
Will Investors Notice Exciting Sign On BeiGene's Chart?
Via Benzinga
Why Shares of BeiGene Were Up Wednesday
The Chinese pharmaceutical stock is experiencing a comeback. 
Via The Motley Fool
What 4 Analyst Ratings Have To Say About BeiGene
Analysts have provided the following ratings for BeiGene (NASDAQ:BGNE) within the last quarter: 
Via Benzinga
Is This Chinese Pharmaceutical Stock Worth the Risk?
BeiGene's shares are down this year, but it has two potential blockbusters. 
Via The Motley Fool
European Heath Agency's Committee Backs Approving BeiGene's Brukinsa In Leukemia Setting
Via Benzinga
Why Leslie's Shares Are Trading Lower By Over 9%? Here Are 60 Stocks Moving In Wednesday's Mid-Day Session
Gainers Biophytis S.A. (NASDAQ: BPTS) shares jumped 114% to $0.7496. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) rose 74.1% to $0.2115. 
Via Benzinga
Workday, XPeng, Titan Machinery And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Analyst Ratings for BeiGene
Analysts have provided the following ratings for BeiGene (NASDAQ:BGNE) within the last quarter: 
Via Benzinga
UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer
Via Benzinga
Why Horizon Therapeutics Shares Are Trading Higher By Over 30%; Here Are 32 Stocks Moving Premarket
Gainers Kalera Public Limited Company (NASDAQ: KAL) shares rose 33.3% to $0.2399 in pre-market trading after jumping 45% on Tuesday. Kalera recently announced restructuring process for German... 
Via Benzinga
Dollar Tree, Dycom Industries, Chico's FAS And Other Big Losers From Tuesday
U.S. stocks closed higher on Tuesday, with the Dow Jones gaining around 400 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Tesla, Amazon, Coupang, Rivian, Beigene: Musk's Share Sale, Antitrust Lawsuit, Earnings Grab Retail Investors' Eyeballs
Major Wall Street indices closed nearly 2% lower on Wednesday after the day was marred by uncertainties including the outcome of the mid-term elections and a sell-off in the cryptocurrency... 
Via Benzinga
Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal
Via Benzinga
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its... 
Via Benzinga
Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million
Deals, financings, trials and approvals on the China biotech/pharma market. 
Via Talk Markets
BeiGene Takes On Johnson & Johnson's Blockbuster Cancer Drug — And Wins
A smaller biotech tested its experimental leukemia drug against J&J's approved med. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades 
Via Benzinga
BeiGene's Brukinsa Shows Superior Progression-Free Survival Versus JNJ's Treatment
Via Benzinga
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors
Via Benzinga
Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay
Key Takeaways: The company logged a revenue fall of 55% in the first half of the year and posted a loss of $131 million Phase 3 clinical trials for its Covid-19 oral drug wrapped up in May but the... 
Via Benzinga
U.S.-China Audit Deal Won't Slow Hong Kong Dual Listing Train, Analysts Say
Key Takeaways: Despite a landmark U.S.-China information-sharing agreement, some predict dual listings in New York and Hong Kong will remain the preferred choice for Chinese... 
Via Benzinga
7 Chinese Stocks to Sell While You Still Can
These Chinese stocks have had a rough outing at the stock markets of late, as their underlying businesses buckle under the economic pressure 
Via InvestorPlace
Why Bed Bath & Beyond Jumped Around 25%; Here Are 68 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Catalent, Tellurian And Other Big Losers From Monday
U.S. stocks closed lower with the Dow Jones dropping around 185 points on Monday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
Why Splunk Is Trading Lower By Around 10%; Here Are 28 Stocks Moving Premarket
Gainers ECMOHO Limited (NASDAQ: MOHO) shares rose 47% to $0.2149 in pre-market trading. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.